Enzymotec Ltd. (ENZY) Upgraded at Zacks Investment Research
Enzymotec Ltd. (NASDAQ:ENZY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “
Separately, Jefferies Group reiterated a “hold” rating on shares of Enzymotec in a report on Thursday, August 4th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/enzymotec-ltd-enzy-upgraded-at-zacks-investment-research.html
Shares of Enzymotec (NASDAQ:ENZY) traded down 4.05% during trading on Tuesday, hitting $7.10. 4,183 shares of the stock traded hands. Enzymotec has a 12 month low of $6.60 and a 12 month high of $10.32. The firm’s 50-day moving average price is $7.31 and its 200-day moving average price is $8.13. The stock has a market cap of $161.30 million, a PE ratio of 37.37 and a beta of 1.27.
Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings results on Tuesday, August 9th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by $0.04. The company earned $15 million during the quarter, compared to the consensus estimate of $14.90 million. Enzymotec had a net margin of 8.37% and a return on equity of 3.12%. The business’s revenue was down 12.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.11 earnings per share. Analysts anticipate that Enzymotec will post $0.27 EPS for the current year.
Several institutional investors have recently modified their holdings of the company. Van ECK Associates Corp boosted its position in shares of Enzymotec by 5.9% in the second quarter. Van ECK Associates Corp now owns 12,659 shares of the company’s stock worth $106,000 after buying an additional 706 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Enzymotec by 12.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 21,313 shares of the company’s stock worth $178,000 after buying an additional 2,298 shares during the last quarter. Menta Capital LLC boosted its position in shares of Enzymotec by 12.4% in the second quarter. Menta Capital LLC now owns 48,488 shares of the company’s stock worth $405,000 after buying an additional 5,362 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its position in shares of Enzymotec by 68.0% in the second quarter. State of New Jersey Common Pension Fund D now owns 22,021 shares of the company’s stock worth $184,000 after buying an additional 8,915 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its position in shares of Enzymotec by 48.6% in the second quarter. Public Employees Retirement System of Ohio now owns 35,187 shares of the company’s stock worth $294,000 after buying an additional 11,501 shares during the last quarter. 36.20% of the stock is owned by institutional investors and hedge funds.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.